Chemed Corporation (CHE) Company Overview

Chemed Corporation, listed on the New York Stock Exchange under ticker CHE, is an unusual diversified services company built around two businesses that share little operational overlap: VITAS Healthcare, a large provider of hospice and palliative-care services, and Roto-Rooter, a national provider of plumbing, drain cleaning, excavation, and water-restoration services. The company describes this structure in its 2025 Form 10-K.

Two service platforms with different customers and economics

Medicare is economically central: more than 90% of VITAS revenue in 2025 came from the Medicare hospice benefit. Its network reaches more than 90% of the U.S. population, giving the brand national recognition while local branches perform the work.

Chemed earns revenue by providing labor-intensive services, but the payment mechanics differ sharply by segment. VITAS is primarily reimbursed under a regulated daily-payment model. Roto-Rooter prices individual jobs and service calls, while franchisees pay population-based fees.

VITAS converts patient census and reimbursement rates into revenue

VITAS revenue is driven mainly by average daily census, the mix of care levels, length of stay, and the Medicare reimbursement rate per patient day. In Q1 2026, average daily census was 22,723, up 2.2% year over year, while admissions increased 6.9% to 19,394. Average revenue per patient per day was $210.62.

Roto-Rooter monetizes urgent jobs, planned projects, and franchise territories

Roto-Rooter generates company-operated revenue from residential and commercial plumbing, drain cleaning, excavation, and water restoration. Demand is often urgent, but lead economics and local capacity still matter. Franchise revenue is structurally lighter: monthly fees are based on territory population and adjusted annually by the consumer price index, rather than being a simple royalty on reported franchisee sales.

VITAS is now the larger growth platform and represented about 64.4% of Chemed’s FY2025 revenue. Roto-Rooter contributed approximately 35.6%. The profit picture is more balanced than the revenue mix because Roto-Rooter historically earns a higher adjusted EBITDA margin. VITAS contributes more growth, while Roto-Rooter can contribute disproportionate cash flow.

Revenue scale and margin quality point in different directions

In FY2025, VITAS adjusted EBITDA was $271.9 million and Roto-Rooter adjusted EBITDA was $204.7 million, before corporate costs. The implied segment margins were approximately 16.7% for VITAS and 22.8% for Roto-Rooter. Therefore, a one-point margin change at either segment can materially alter consolidated earnings even when revenue growth appears modest.

The quarter ended March 31, 2026 showed a split result: VITAS continued to expand, but Roto-Rooter faced weather disruption, weaker conversion, and elevated paid-marketing expense. Chemed reported consolidated revenue of $657.5 million, operating income of $84.6 million, GAAP net income of $66.3 million, and diluted EPS of $4.84. Adjusted diluted EPS was $5.65, up 0.4% year over year. The official Q1 2026 earnings release provides the freshest operating detail, while the accompanying Form 10-Q supplies the statutory financial statements.

VITAS growth offset a difficult Roto-Rooter quarter

VITAS admissions rose faster than census, an important signal because admissions replenish the patient base. At Roto-Rooter, leads increased 3.3%, yet revenue declined, indicating that conversion, service mix, weather, or job execution weakened the value captured from each lead. Management estimated that severe weather affecting 24 branches reduced revenue by roughly $3 million to $4 million, while paid marketing expense was approximately $2 million above expectations.

Management’s 2026 guidance frames the recovery test

Chemed’s Q1 outlook called for VITAS average daily census growth of 4.5% to 5.5%, revenue growth excluding Medicare cap of 6.5% to 7.5%, and an adjusted EBITDA margin excluding cap of 18.0% to 18.5%. For Roto-Rooter, management expected revenue growth of 3.0% to 3.5% and an adjusted EBITDA margin of 21.5% to 22.5%. Consolidated adjusted EPS guidance was $24.00 to $24.75. Execution now depends on Roto-Rooter conversion and VITAS growth without excess labor or cap pressure.

Chemed’s history matters because the present company is the product of deliberate portfolio construction rather than organic expansion from one core industry. The official company history and filings show how a former specialty-products group evolved into a services holding company focused on decentralized operating autonomy and central capital allocation.

1. 1970–1971
   Chemed was incorporated in Delaware and succeeded W.R. Grace’s Special Products Group. This origin established the corporate platform and portfolio-management mindset.
2. 1982
   The company ceased being a W.R. Grace subsidiary. Independence made capital allocation, acquisitions, and portfolio reshaping central board responsibilities.
3. 1996
   Chemed acquired the remaining Roto-Rooter shares it did not own. Full control converted an established brand into a consolidated cash-generating operating platform.
4. 2004
   Chemed acquired VITAS for approximately $406 million including assumed debt and refinancing. The transaction transformed healthcare services into the company’s long-term growth engine.
5. 2024
   VITAS purchased selected Covenant hospice operations and an assisted-living facility for $85 million, expanding geographic density and showing a willingness to use acquisitions selectively.
6. 2026
   Roto-Rooter acquired the San Francisco and Fort Worth franchise territories for $20.6 million. The move added company-operated exposure to territories covering about 3.3 million people.

Why decentralization still defines the operating model

Chemed reports few integrated operating functions between VITAS and Roto-Rooter. Local operating knowledge is essential in both businesses: hospice programs manage referral relationships, clinical staffing, and regional reimbursement conditions, while Roto-Rooter branches manage technicians, local advertising, routing, and job economics. Corporate headquarters therefore has more leverage over capital deployment, governance, financing, and executive incentives than over daily service delivery.

This history explains Chemed’s strategic discipline. It needs each platform to maintain service quality, produce cash, and offer attractive reinvestment opportunities. That makes acquisition integration, local management quality, and corporate capital allocation more important than conventional conglomerate synergies.

Chemed’s moat is not a single patent or network effect. It is a combination of regulated operating know-how, branch density, trusted brands, referral relationships, labor-management systems, and the financial capacity to reinvest. These resources are difficult to reproduce simultaneously, although neither business is immune to competition.

VITAS benefits from scale in a fragmented, regulated care market

VITAS operated under 33 Medicare provider numbers at year-end 2025. Scale supports compliance infrastructure, centralized billing, clinical protocols, recruiting, data analysis, and relationships with hospitals and physicians. The barrier is not only obtaining a license; a competitor must recruit clinicians, build referral credibility, manage quality, and navigate Medicare documentation and cap rules consistently.

Roto-Rooter combines brand recognition with local service capacity

The Roto-Rooter name has been used since 1935, and the system’s national coverage makes it easier to attract urgent residential demand than for an unknown local entrant. Competitive advantage depends on branch availability, technician density, call-center and digital-lead performance, equipment, training, and the ability to respond quickly. Local and regional competitors still exert pricing and marketing pressure.

From a Five Forces perspective, rivalry is meaningful in both segments and labor has bargaining power because qualified clinicians and technicians are essential. Buyer power is limited for an emergency plumbing customer but higher for commercial accounts and healthcare referral sources. Regulation raises entry barriers for hospice while simultaneously limiting pricing freedom. Chemed’s advantage is therefore best described as execution-based durability rather than immunity from competition.

Chemed entered 2026 with a profitable operating base and strong cash-generation history, but its balance sheet changed materially after aggressive repurchases. FY2025 revenue rose 4.1% to $2.530 billion, while GAAP operating income fell to $338.2 million and net income fell to $265.2 million. Adjusted EBITDA was $458.7 million. The FY2025 results release provides the annual baseline.

Cash conversion remains the financial foundation

This conversion ratio illustrates why Chemed has historically been able to repurchase shares and pay dividends while still investing in operations. The service businesses do not require heavy factories or inventory. Acquisition spending, working capital, debt service, and expansion also consume capital.

Share repurchases increased financial leverage

At March 31, 2026, Chemed held $16.9 million of cash and reported $91.2 million of long-term debt. In April 2026, it established a $450 million revolving credit facility with a $250 million expansion feature; available capacity was approximately $313.3 million excluding $45.5 million of letters of credit. The repurchase pace makes buyback prices, borrowing, and operating cash flow increasingly important.

Chemed has one common share class and no founder-controlled voting structure. Its ownership is therefore dispersed and institutionally influenced. The 2026 proxy statement, using ownership information as of December 31, 2025, identified Vanguard and BlackRock as the largest beneficial owners. This structure increases the importance of board accountability and capital-allocation discipline.

Incentives emphasize per-share results and capital efficiency

Chemed’s executive framework uses adjusted EPS and return on assets in annual incentives, while longer-term awards incorporate cumulative adjusted EPS and relative total shareholder return. Those measures fit a holding company whose corporate center allocates cash between reinvestment, acquisitions, dividends, and repurchases. The board’s published governance documents also make committee oversight visible. The governance question is whether incentives reward durable improvement rather than buyback-driven per-share growth.

Chemed’s two segments diversify revenue sources, but they also create two separate operating-risk systems. VITAS is exposed to reimbursement, clinical quality, staffing, referral patterns, audits, and Medicare cap calculations. Roto-Rooter is exposed to weather, local competition, technician supply, marketing efficiency, service execution, and consumer or commercial demand. Each risk should be tied to measurable financial lines.

Which operating KPIs deserve the closest attention?

Opportunity and risk are closely linked. Population aging and broader hospice acceptance can expand VITAS demand, but rapid census growth must be matched by clinicians, compliant care delivery, and provider-level cap management. Roto-Rooter can improve through pricing, territory acquisitions, digital conversion, and branch productivity, but the Q1 2026 result showed that more leads do not automatically create more revenue or profit.

A Chemed valuation should model the segments separately before consolidating them. VITAS requires assumptions for patient census, admissions, reimbursement per day, labor intensity, care mix, Medicare cap deductions, and margin. Roto-Rooter requires assumptions for leads, conversion, average ticket, service mix, branch productivity, marketing expense, and acquired territories. Corporate costs, taxes, capex, working capital, debt, dividends, and repurchases then determine per-share value.

The DCF hinges on growth quality, not only headline growth

The most important forecast relationship is the conversion of revenue growth into free cash flow. Higher VITAS census is valuable only if reimbursement, labor, and cap management preserve incremental margin. Higher Roto-Rooter lead volume is valuable only if branches convert those leads into profitable jobs. Terminal-value assumptions should also reflect regulatory exposure in hospice, local-service competition, and the possibility that recent repurchases leave less balance-sheet flexibility during an operating setback.

For students and researchers, Chemed is a useful case in portfolio strategy: the segments share capital discipline rather than customers. For investors, the analytical task is to avoid letting consolidated figures hide divergent segment trends. Its financial reports should be read with segment KPIs, cash deployment, and reimbursement exposure side by side.